BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31455412)

  • 1. Metabolic profiling reveals distinct metabolic alterations in different subtypes of pituitary adenomas and confers therapeutic targets.
    Feng J; Gao H; Zhang Q; Zhou Y; Li C; Zhao S; Hong L; Yang J; Hao S; Hong W; Zhuang Z; Xu G; Zhang Y
    J Transl Med; 2019 Aug; 17(1):291. PubMed ID: 31455412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes.
    Salomon MP; Wang X; Marzese DM; Hsu SC; Nelson N; Zhang X; Matsuba C; Takasumi Y; Ballesteros-Merino C; Fox BA; Barkhoudarian G; Kelly DF; Hoon DSB
    Clin Cancer Res; 2018 Sep; 24(17):4126-4136. PubMed ID: 30084836
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses.
    Moreno CS; Evans CO; Zhan X; Okor M; Desiderio DM; Oyesiku NM
    Cancer Res; 2005 Nov; 65(22):10214-22. PubMed ID: 16288009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype.
    Chen Y; Gao H; Xie W; Guo J; Fang Q; Zhao P; Liu C; Zhu H; Wang Z; Wang J; Gui S; Zhang Y; Li C
    Aging (Albany NY); 2020 Dec; 13(1):1276-1293. PubMed ID: 33472173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells.
    Yoshida D; Koketshu K; Nomura R; Teramoto A
    J Neurooncol; 2010 Oct; 100(1):51-64. PubMed ID: 20309720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
    Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G
    Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing of microRNAs reveals a unique expression pattern in different types of pituitary adenomas.
    He Z; Chen L; Hu X; Tang J; He L; Hu J; Fei F; Wang Q
    Endocr J; 2019 Aug; 66(8):709-722. PubMed ID: 31061247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
    Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
    J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels.
    Hofland LJ; Velkeniers B; vd Lely AJ; van Koetsveld PM; Kazemzadeh M; Waaijers M; Hooghe-Peters EL; Lamberts SW
    Clin Endocrinol (Oxf); 1992 Sep; 37(3):240-8. PubMed ID: 1424206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of ghrelin in somatotroph and other types of pituitary adenomas.
    Wasko R; Jaskula M; Kotwicka M; Andrusiewicz M; Jankowska A; Liebert W; Sowinski J
    Neuro Endocrinol Lett; 2008 Dec; 29(6):929-38. PubMed ID: 19112387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Invasive-Related Biomarker in Three Subtypes of Nonfunctioning Pituitary Adenomas.
    Chen Y; Chuan HL; Yu SY; Li CZ; Wu ZB; Li GL; Zhang YZ
    World Neurosurg; 2017 Apr; 100():514-521. PubMed ID: 28093347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
    Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
    Casar-Borota O; Øystese KA; Sundström M; Melchior L; Popovic V
    Pituitary; 2016 Aug; 19(4):407-14. PubMed ID: 27097804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The release of leptin and its effect on hormone release from human pituitary adenomas.
    Korbonits M; Chitnis MM; Gueorguiev M; Norman D; Rosenfelder N; Suliman M; Jones TH; Noonan K; Fabbri A; Besser GM; Burrin JM; Grossman AB
    Clin Endocrinol (Oxf); 2001 Jun; 54(6):781-9. PubMed ID: 11422113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.
    Sakai N; Kim K; Sanno N; Yoshida D; Teramoto A; Shibasaki T
    Neurol Med Chir (Tokyo); 2008; 48(11):481-7; discussion 487-8. PubMed ID: 19029774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor subtype gene expression in pituitary adenomas.
    Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel somatic variants involved in biochemical activity of pure growth hormone-secreting pituitary adenoma without GNAS variant.
    Ku CR; Lim H; Lee YJ; Kim SH; Kim D; Kim SH; Lee MK; Bang D; Lee EJ
    Sci Rep; 2021 Aug; 11(1):16530. PubMed ID: 34400688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular classification of pituitary adenomas: in search for criteria useful for high-throughput studies.
    Żebracka-Gala J; Rudnik A; Hasse-Lazar K; Larysz D; Jarząb M; Krajewska J; Bażowski P; Jarząb B
    Endokrynol Pol; 2016; 67(2):148-56. PubMed ID: 26884293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23-24.
    Yamasaki H; Mizusawa N; Nagahiro S; Yamada S; Sano T; Itakura M; Yoshimoto K
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):464-70. PubMed ID: 12641630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.